Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial
Phenolic acid-rich fraction from Anisopus mannii (PhAM) contains abundance of ferulic acid, gallic acid, protocatechuic acid, and syringic acid. Among other glycolytic enzymes, in vitro, PhAM counteracted the binding of sodium orthovanadate to phosphofructokinase 1 (PFK-1), improving its activities....
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Pharmacological Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661825000271 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825199560957362176 |
|---|---|
| author | Peter U. Amadi Justice O. Osuoha Chidi N. Ekweogu Suha J. Jarad Esienanwan E. Efiong Prince C. Odika Chioma Ejiofor Oluchi Aloy-Amadi Govind S. Gill Chiamaka W. Adumekwe Ailun Gaowa Dawei Zhang Barbora de Courten Emmanuel N. Agomuo |
| author_facet | Peter U. Amadi Justice O. Osuoha Chidi N. Ekweogu Suha J. Jarad Esienanwan E. Efiong Prince C. Odika Chioma Ejiofor Oluchi Aloy-Amadi Govind S. Gill Chiamaka W. Adumekwe Ailun Gaowa Dawei Zhang Barbora de Courten Emmanuel N. Agomuo |
| author_sort | Peter U. Amadi |
| collection | DOAJ |
| description | Phenolic acid-rich fraction from Anisopus mannii (PhAM) contains abundance of ferulic acid, gallic acid, protocatechuic acid, and syringic acid. Among other glycolytic enzymes, in vitro, PhAM counteracted the binding of sodium orthovanadate to phosphofructokinase 1 (PFK-1), improving its activities. In a rat model of diet-induced diabetes, PhAM monotherapy reduced HbA1c by an average of 0.63 % and fasting plasma glucose by 25 mg/dl. This herb rescued β-cells from streptozotocin-mediated destruction, thereby improving glycemic control. Supported by the preclinical trial, eighty-five patients with type 2 diabetes (T2D) receiving first-line medications were enrolled in a double-blind, randomized, placebo-controlled trial with a 90 % power level. Patients were randomized into a placebo group or either of the following two treatment groups: oral administration of 12 mg or 20 mg/kg body weight of PhAM once every 48 h for 6 months. Both treatments were well tolerated. At the endpoint, more than 70 % of patients achieved a 0.5 – 2.0 decrease in HbA1c levels and a > 20 mg/dl decrease in fasting blood glucose, meeting the pre-specified primary outcome. 66 % of patients treated with 20 mg PhAM achieved the < 7 % HbA1c and HOMA-IR of > 1.0 goal. respectively. Our study shows that PhAM can supplement first-line medications to achieve target glycemic control within 6 months. |
| format | Article |
| id | doaj-art-36377f199c9345d8a1f68329fe612f6c |
| institution | Kabale University |
| issn | 1096-1186 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pharmacological Research |
| spelling | doaj-art-36377f199c9345d8a1f68329fe612f6c2025-02-08T04:59:48ZengElsevierPharmacological Research1096-11862025-02-01212107602Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trialPeter U. Amadi0Justice O. Osuoha1Chidi N. Ekweogu2Suha J. Jarad3Esienanwan E. Efiong4Prince C. Odika5Chioma Ejiofor6Oluchi Aloy-Amadi7Govind S. Gill8Chiamaka W. Adumekwe9Ailun Gaowa10Dawei Zhang11Barbora de Courten12Emmanuel N. Agomuo13Department of Pediatrics, Group on the Molecular and Cell Biology of Lipids, University of Alberta, Canada; Department of Biochemistry, Imo State University, Owerri, Nigeria; Corresponding author at: Department of Pediatrics, Group on the Molecular and Cell Biology of Lipids, University of Alberta, Canada.School of Chemistry, Monash University, AustraliaDepartment of Medical Biochemistry, Imo State University, Owerri, NigeriaDepartment of Pediatrics, Group on the Molecular and Cell Biology of Lipids, University of Alberta, Canada; Department of Biochemistry, Group on the Molecular and Cell Biology of Lipids, University of Alberta, CanadaInstitute of Epidemiology, Helmholtz Zentrum München, 85764 Neuherberg, GermanyDepartment of Biology, St. Mary’s University, Halifax, CanadaDepartment of Biochemistry, Federal University of Technology, Owerri, NigeriaDepartment of Medical Laboratory Science, Imo State University, Owerri, NigeriaDepartment of Pediatrics, Group on the Molecular and Cell Biology of Lipids, University of Alberta, CanadaDepartment of Biochemistry, Imo State University, Owerri, NigeriaDepartment of Pediatrics, Group on the Molecular and Cell Biology of Lipids, University of Alberta, CanadaDepartment of Pediatrics, Group on the Molecular and Cell Biology of Lipids, University of Alberta, CanadaSchool of Health and Biomedical Sciences, RMIT University, Melbourne, Australia; Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, AustraliaDepartment of Biochemistry, Imo State University, Owerri, NigeriaPhenolic acid-rich fraction from Anisopus mannii (PhAM) contains abundance of ferulic acid, gallic acid, protocatechuic acid, and syringic acid. Among other glycolytic enzymes, in vitro, PhAM counteracted the binding of sodium orthovanadate to phosphofructokinase 1 (PFK-1), improving its activities. In a rat model of diet-induced diabetes, PhAM monotherapy reduced HbA1c by an average of 0.63 % and fasting plasma glucose by 25 mg/dl. This herb rescued β-cells from streptozotocin-mediated destruction, thereby improving glycemic control. Supported by the preclinical trial, eighty-five patients with type 2 diabetes (T2D) receiving first-line medications were enrolled in a double-blind, randomized, placebo-controlled trial with a 90 % power level. Patients were randomized into a placebo group or either of the following two treatment groups: oral administration of 12 mg or 20 mg/kg body weight of PhAM once every 48 h for 6 months. Both treatments were well tolerated. At the endpoint, more than 70 % of patients achieved a 0.5 – 2.0 decrease in HbA1c levels and a > 20 mg/dl decrease in fasting blood glucose, meeting the pre-specified primary outcome. 66 % of patients treated with 20 mg PhAM achieved the < 7 % HbA1c and HOMA-IR of > 1.0 goal. respectively. Our study shows that PhAM can supplement first-line medications to achieve target glycemic control within 6 months.http://www.sciencedirect.com/science/article/pii/S1043661825000271DiabetesPhosphofructokinase 1Randomized trialHbA1cAnisopus mannii |
| spellingShingle | Peter U. Amadi Justice O. Osuoha Chidi N. Ekweogu Suha J. Jarad Esienanwan E. Efiong Prince C. Odika Chioma Ejiofor Oluchi Aloy-Amadi Govind S. Gill Chiamaka W. Adumekwe Ailun Gaowa Dawei Zhang Barbora de Courten Emmanuel N. Agomuo Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial Pharmacological Research Diabetes Phosphofructokinase 1 Randomized trial HbA1c Anisopus mannii |
| title | Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial |
| title_full | Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial |
| title_fullStr | Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial |
| title_full_unstemmed | Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial |
| title_short | Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial |
| title_sort | phenolic acids from anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes a double blind randomized clinical trial |
| topic | Diabetes Phosphofructokinase 1 Randomized trial HbA1c Anisopus mannii |
| url | http://www.sciencedirect.com/science/article/pii/S1043661825000271 |
| work_keys_str_mv | AT peteruamadi phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial AT justiceoosuoha phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial AT chidinekweogu phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial AT suhajjarad phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial AT esienanwaneefiong phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial AT princecodika phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial AT chiomaejiofor phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial AT oluchialoyamadi phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial AT govindsgill phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial AT chiamakawadumekwe phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial AT ailungaowa phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial AT daweizhang phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial AT barboradecourten phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial AT emmanuelnagomuo phenolicacidsfromanisopusmanniimodulatesphosphofructokinase1toimproveglycemiccontrolinpatientswithtype2diabetesadoubleblindrandomizedclinicaltrial |